Novo Nordisk, FDA
Digest more
La apuesta de Novo Nordisk por México se afianza con Ozempic y un futuro fármaco oral para obesidad, en un país marcado por el avance de la diabetes y el envejecimiento.
Investing.com - Las bolsas europeas operaron mixtas en las primeras operaciones del martes, con desarrollos regionales clave que incluyen un salto en las acciones de Novo Nordisk tras obtener aprobación regulatoria para su píldora GLP-1 contra la obesidad, y datos recientes que muestran una disminución en las ventas de Tesla en Europa en noviembre.
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the U.S. ・Lilly strengthens its leadership with a deep pipeline, while Novo faces slowing growth,
The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and Ozempic to $349 a month Nov. 17, down from $499 a month, for ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, Novo Nordisk, has announced it will cut 9,000 jobs weeks ...